CSA Medical, Inc., a Baltimore, Maryland-based developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body, has secured $20.5m in a Series B financing.
The round was led by Intersouth Partners and First Analysis, with participation from S.V. Life Sciences, Rose Park, Blue Heron Capital and other existing investors.
In conjunction with the funding, Tracy Marshbanks, Ph.D., from First Analysis, Rick Kent, M.D., of Intersouth Partners and Paul LaViolette from S.V. Life Sciences will join CSA Medical’s Board of Directors.
The company intends to use the funding for the growth and expansion of its patented and currently marketed Spray Cryotherapy system, which is comprised of a device and specialty catheters that allow delivery of therapeutic doses of a cryogen to freeze and destroy unwanted tissue inside the body. It is being used at more than 80 top-ranked cancer centers and academic teaching hospitals throughout the United States.
CSA Medical is led by CEO and President Bill Floyd.